Patents Assigned to SULFATEQ B.V.
-
Patent number: 11006626Abstract: This invention is related to a compound with the structural formula (I) wherein, R1, and R2 are independently selected from the group consisting of C1-C6 alkyl and is preferably methyl, ethyl, propyl or isopropyl; R3 is selected from the group consisting of CH2NHR9, C(?O)YR10, —CH2OHType: GrantFiled: September 27, 2018Date of Patent: May 18, 2021Assignee: Sulfateq B.V.Inventors: Adrianus Cornelis Van Der Graaf, Andre Heeres, Johannes Paulus Gerardus Seerden
-
Patent number: 10676452Abstract: The present invention relates to compounds for prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially to compounds for prophylaxis or treatment of diabetic kidney damage. Specifically, the present invention relates to 6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially diabetic kidney organ damage.Type: GrantFiled: May 12, 2016Date of Patent: June 9, 2020Assignee: Sulfateq B.V.Inventors: Adrianus Cornelis Van Der Graaf, Robert Henk Henning, Leo Edwin Deelman, Gerrit Jan Willem Euverink
-
Patent number: 10426771Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug deliver devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl) (piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).Type: GrantFiled: January 26, 2018Date of Patent: October 1, 2019Assignee: Sulfateq B.V.Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
-
Patent number: 10322124Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug delivery devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).Type: GrantFiled: January 26, 2018Date of Patent: June 18, 2019Assignee: Sulfateq B.V.Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
-
Patent number: 10123529Abstract: This invention is related to a compound with the structural formula (I) wherein, R1, and R2 are independently selected from the group consisting of C1-C6 alkyl and is preferably methyl, ethyl, propyl or isopropyl; R3 is selected from the group consisting of CH2NHR9, C(?O)YR10, —CH2OHType: GrantFiled: December 18, 2013Date of Patent: November 13, 2018Assignee: Sulfateq B.V.Inventors: Adrianus Cornelis Van Der Graaf, Andre Heeres, Johannes Paulus Gerardus Seerden
-
Publication number: 20180280384Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug deliver devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl) (piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: January 26, 2018Publication date: October 4, 2018Applicant: Sulfateq B.V.Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
-
Publication number: 20180250294Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug delivery devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: January 26, 2018Publication date: September 6, 2018Applicant: Sulfateq B.V.Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
-
Publication number: 20180170892Abstract: The present invention relates to compounds for prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially to compounds for prophylaxis or treatment of diabetic kidney damage. Specifically, the present invention relates to 6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially diabetic kidney organ damage.Type: ApplicationFiled: May 12, 2016Publication date: June 21, 2018Applicant: Sulfateq B.V.Inventors: Adrianus Cornelis VAN DER GRAAF, Robert Henk HENNING, Leo Edwin DEELMAN, Gerrit Jan Willem EUVERINK
-
Patent number: 9913841Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug delivery devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-di-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).Type: GrantFiled: June 17, 2015Date of Patent: March 13, 2018Assignee: Sulfateq B.V.Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
-
Publication number: 20150342174Abstract: This invention is related to a compound with the structural formula (I) wherein, R1, and R2 are independently selected from the group consisting of C1-C6 alkyl and is preferably methyl, ethyl, propyl or isopropyl; R3 is selected from the group consisting of CH2NHR9, C(?O)YR10, —CH2OHType: ApplicationFiled: December 18, 2013Publication date: December 3, 2015Applicant: SULFATEQ B.V.Inventors: Adrianus Cornelis VAN DER GRAAF, Andre HEERES, Johannes Paulus Gerardus SEERDEN
-
Publication number: 20130203830Abstract: The invention is related to compounds for prevention of cell injury or protection of cells. The compounds are involved in the maintenance or the increase of hydrogen sulphide in cells, which results in a protection of the cells or the prevention of cell injury. The compounds of the invention can be used in cell culture and tissue culture techniques. They can also be used in several medical conditions such as ischemia, reperfusion and hypothermia, or for preserving organs which are used for transplantation.Type: ApplicationFiled: April 18, 2011Publication date: August 8, 2013Applicant: SULFATEQ B.V.Inventors: Fatemeh Talaei, Robert Henk Henning, Adrianus C. Van der Graaf